Apellis Pharmaceuticals Stock Alpha and Beta Analysis
| APLS Stock | USD 24.66 0.29 1.19% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Apellis Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Apellis Pharmaceuticals over a specified time horizon. Remember, high Apellis Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Apellis Pharmaceuticals' market risk premium analysis include:
Beta 0.94 | Alpha (0.30) | Risk 3.23 | Sharpe Ratio (0.14) | Expected Return (0.46) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Apellis |
Apellis Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Apellis Pharmaceuticals market risk premium is the additional return an investor will receive from holding Apellis Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Apellis Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Apellis Pharmaceuticals' performance over market.| α | -0.3 | β | 0.94 |
Apellis Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Apellis Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Apellis Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Apellis Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Apellis Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Apellis Pharmaceuticals shares will generate the highest return on investment. By understating and applying Apellis Pharmaceuticals stock market price indicators, traders can identify Apellis Pharmaceuticals position entry and exit signals to maximize returns.
Apellis Pharmaceuticals Return and Market Media
The median price of Apellis Pharmaceuticals for the period between Sun, Dec 15, 2024 and Sat, Mar 15, 2025 is 29.73 with a coefficient of variation of 10.48. The daily time series for the period is distributed with a sample standard deviation of 3.13, arithmetic mean of 29.83, and mean deviation of 2.64. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 874 shares by Pascal Deschatelets of Apellis Pharmaceuticals at 64.1382 subject to Rule 16b-3 | 12/13/2024 |
2 | Disposition of tradable shares by Jeffrey Eisele of Apellis Pharmaceuticals at 33.09 subject to Rule 16b-3 | 12/23/2024 |
3 | Acquisition by Chan Gerald of 11199 shares of Apellis Pharmaceuticals at 31.91 subject to Rule 16b-3 | 12/31/2024 |
4 | Acquisition by Dunlop A. Sinclair of 6267 shares of Apellis Pharmaceuticals subject to Rule 16b-3 | 01/03/2025 |
5 | Insider Trading | 01/08/2025 |
6 | Disposition of 1096 shares by Chopas James George of Apellis Pharmaceuticals at 30.4255 subject to Rule 16b-3 | 01/22/2025 |
7 | Disposition of 365 shares by Mark Delong of Apellis Pharmaceuticals at 29.5236 subject to Rule 16b-3 | 01/29/2025 |
8 | Which Small-Cap Medical Innovator Excels in Institutional Backing and Financial Performance | 02/26/2025 |
9 | What To Expect From Apellis Pharmaceuticals Inc Q4 2024 Earnings | 02/27/2025 |
10 | Apellis Pharmaceuticals Inc Reports Strong 2024 Financial Results with 97 percent Revenue Growth | 02/28/2025 |
11 | Apellis Q4 Loss Narrower Than Expected, Syfovre Sales Drive Revenues | 03/03/2025 |
12 | Disposition of 6667 shares by Watson David O. of Apellis Pharmaceuticals subject to Rule 16b-3 | 03/04/2025 |
13 | Research Analysts Offer Predictions for APLS Q1 Earnings | 03/05/2025 |
14 | Steward Partners Investment Advisory LLC Buys 2,250 Shares of Apellis Pharmaceuticals, Inc. | 03/07/2025 |
About Apellis Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Apellis or other stocks. Alpha measures the amount that position in Apellis Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Days Sales Outstanding | 37.39 | 190.0 | 136.2 | 72.86 | PTB Ratio | 32.3 | 36.52 | 17.3 | 18.84 |
Apellis Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Apellis Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Apellis Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Apellis Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Apellis Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Apellis Pharmaceuticals' management manipulating its earnings.
| 20th of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Apellis Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.